The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort-Reference-Cited by-同舟云学术

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Published:2018-07-23 Issue:14 Volume:2 Page:1765-1772
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Stahl Maximilian¹,DeVeaux Michelle²,de Witte Theo³,Neukirchen Judith⁴,Sekeres Mikkael A.⁵,Brunner Andrew M.⁶,Roboz Gail J.⁷,Steensma David P.⁸,Bhatt Vijaya R.⁹,Platzbecker Uwe¹⁰¹¹,Cluzeau Thomas¹²,Prata Pedro H.¹³,Itzykson Raphaël¹³,Fenaux Pierre¹³,Fathi Amir T.⁶,Smith Alexandra¹⁴,Germing Ulrich⁴,Ritchie Ellen K.⁷,Verma Vivek⁹,Nazha Aziz⁵,Maciejewski Jaroslaw P.⁵,Podoltsev Nikolai A.¹,Prebet Thomas¹,Santini Valeria¹⁵,Gore Steven D.¹,Komrokji Rami S.¹⁶,Zeidan Amer M.¹

Affiliation:

1. Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;

2. Department of Biostatistics, Yale School of Public Health, New Haven, CT;

3. Department of Tumorimmunology, Radboudumc, Nijmegen, The Netherlands;

4. Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany;

5. Leukemia Program, Cleveland Clinic, Cleveland, OH;

6. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;

7. Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY;

8. Dana-Farber Cancer Institute, Boston, MA;

9. University of Nebraska Medical Center, Omaha, NE;

10. Universitätsklinikum “Carl Gustav Carus” der Technischen Universität Dresden, Dresden, Germany;

11. German Cancer Consortium and National Center for Tumor Diseases Dresden, Dresden, Germany;

12. Centre Hospitalier Universitaire Nice, Nice, France;

13. Saint-Louis Hospital, University Paris 7, Paris, France;

14. Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;

15. Division of Hematology, University of Florence, Azienda Ospedaliero Universitaria Carreggi, Florence, Italy; and

16. Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL

Abstract

Key Points IST leads to a response in nearly half, and to RBC transfusion independence in about a third, of selected lower-risk MDS patients. Hypocellularity of bone marrow and the use of horse ATG plus cyclosporine are associated with increased rates of transfusion independence.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/14/1765/881160/advances019414.pdf

Reference49 articles.

1. How we treat lower-risk myelodysplastic syndromes;Fenaux;Blood,2013

2. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome;Biesma;Cancer,1997

3. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan;Teramura;Blood,2007

4. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes;Montoro;Ann Hematol,2018

5. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes;Molldrem;Ann Intern Med,2002

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical decision-making and treatment of myelodysplastic syndromes;Blood;2023-12-28

2. Next-generation therapy for lower-risk MDS;Hematology;2023-12-08

3. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists;Clinics in Laboratory Medicine;2023-12

4. Treatment of Myelodysplastic Syndromes;Cancer Consult;2023-11-18

5. Traitement des syndromes myélodysplasiques de bas risque;Bulletin du Cancer;2023-11